Chuck Bramlage, MBA
Chief Executive Officer
- Launched 28 products in 15 therapeutic areas
- CEO of Pearl Therapeutics from 2011-2016 which was sold in 2013 to Astra Zeneca for $1.1B.
- Previously COO of Pharmaceutical Products at Covidien, President of European operations at Valeant and President and CEO of Battelle Pharma, various commercial positions of increasing responsibility at Merck and GSK
Dr. Tom Megerian
CMO & EVP of Clinical Dev.
- 20+ years of designing and executing clinical trials and leading clinical development programs
- Previously VP of Clinical Dev. at Avanir and VP for Strategic Medical Science in the Codman Neuroscience Division of J&J
- MD PhD (Neuroscience) from Northwestern University, Neurology training at the Harvard-Longwood Program and Fellowship in Behavioral Child Neurology at the Boston Children’s Hospital
Brian Cahill
Chief Financial Officer
- 20+ years of finance, strategic planning and project management experience
- Previously Chief Financial Officer at Eagle Pharmaceuticals, Corporate Controller at Aralez Pharmaceuticals and Executive Director, Assistant Controller at Par, with a decade of public accounting experience
- BS in Accounting from Manhattan University
Eugene Prahin, MBA
Chief Administrative Officer
- 20+ years of finance, operations and investment management experience
- Other roles include COO at Sparrow Capital, as well as positions with GSC Group and Lehman Brothers
- MBA from the London Business School and BSc in Management from SUNY Binghamton
Dr. Tracy Fischer
SVP, Regulatory & Quality
- 20+ years of experience in regulatory affairs and clinical development
- Previously Sr. Director of Reg. Affairs for Pearl Therapeutics, and held positions in clinical dev. and reg. affairs at GlaxoSmithKline
- PharmD from University of Maryland, Post-doctorate residency and fellowship training at University of Kentucky and at University of North Carolina / GSK
Uyen Nguyen
VP, Clinical Operations
- 20+ years in R&D and clinical research operations
- Held key roles in clinical ops. for Prometheus, Spectrum Pharmaceuticals and Pfizer
- At Avanir Pharmaceuticals managed the Phase 2 study of [AVP-923] which received positive outcomes. Once Avanir was acquired by Otsuka Holdings, she was placed in the lead role for their flagship clinical program consisting of 4 large U.S. and global Phase 3 trials